<DOC>
	<DOCNO>NCT02420262</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial compare efficacy safety insulin degludec/liraglutide ( IDegLira ) versus basal-bolus therapy combination metformin subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Clinical Trial Comparing Efficacy Safety Insulin Degludec/Liraglutide ( IDegLira ) Versus Basal-bolus Therapy Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male female , age least 18 year time signing informed consent Type 2 diabetes subject ( diagnose clinically ) least 6 month prior screen HbA1c ( glycosylated haemoglobin ) 7.010.0 % [ 53mmol/mol86mmol/mol ] ( inclusive ) central laboratory analysis Current treatment IGlar ( insulin glargine ) least 90 calendar day prior screen Stable daily dose IGlar 20 unit 50 unit ( inclusive ) least 56 calendar day prior screen . Individual fluctuation plus/minus 10 % within 56 calendar day prior screen acceptable , however day screen total daily dose within range 20 units50 unit inclusive Stable daily dose metformin ( least 1500 mg max tolerate dose ) least 90 calendar day prior screen Body mass index ( BMI ) equal 40 kg/m^2 Treatment medication indication diabetes obesity state inclusion criterion period 90 calendar day screen Anticipated initiation change concomitant medication excess 14 calendar day know affect weight glucose metabolism , weight loss/modifying ( e.g . ; sibutramine , orlistat , thyroid hormone , corticosteroid ) Impaired liver function , define alanine aminotransferase ( ALT ) least 2.5 time upper limit normal Renal impairment eGFR ( electronic case report form ) 60 mL/min/1.73 m^2 per CKDEPI ( Chronic Kidney Disease Epidemiology Collaboration ) Screening calcitonin least 50 ng/L History pancreatitis ( acute chronic ) Personal family history medullary thyroid carcinoma multiple endocrine neoplasia type 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>